Literature DB >> 9384677

CD80-transfected human breast and ovarian tumor cell lines: improved immunogenicity and induction of cytolytic CD8+ T lymphocytes.

B Gückel1, M Lindauer, W Rudy, A Habicht, M Siebels, S Kaul, G Bastert, S C Meuer, U Moebius.   

Abstract

Human tumor cell lines derived from breast and ovarian carcinomas have been found to be ineffective in stimulating the induction phase of an immune response such as T cell proliferation in allogeneic mixed tumor cell lymphocyte cultures. Since representative tumor cell lines are effectively lysed by activated T lymphocytes, the induction of an effector phase is not impaired. In order to reconstitute the potential to induce primary T cell activation, we transfected CD80 into a breast (KS) and an ovarian carcinoma (GG) cell line. CD80 expression in KS cells resulted in improved primary T cell activation, whereas it was ineffective in the case of GG cells. However, treatment of CD80-transfected GG cells with INF-gamma rendered them immunogenic, and resulted in T cell proliferation. Likewise, TNF-alpha and/or INF-gamma augmented T cell proliferation induced by CD80-transfected KS cells. Furthermore, T lymphocytes stimulated with cytokine-treated CD80+ KS cells gave rise to a long term proliferating CD8+ CTL line with class I MHC restricted cytolytic antitumor activity. These studies emphasize the requirement for costimulation in generating tumor-specific immunity, and demonstrate the efficacy of CD80 in generating CD8+ cytolytic T lymphocytes.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9384677

Source DB:  PubMed          Journal:  Cytokines Mol Ther        ISSN: 1355-6568


  6 in total

1.  Bladder cancer immunogenicity: expression of CD80 and CD86 is insufficient to allow primary CD4+ T cell activation in vitro.

Authors:  S J Pettit; S Ali; E O'Flaherty; T R Griffiths; D E Neal; J A Kirby
Journal:  Clin Exp Immunol       Date:  1999-04       Impact factor: 4.330

Review 2.  Specific immunotherapy of cancer in elderly patients.

Authors:  S Matzku; M Zöller
Journal:  Drugs Aging       Date:  2001       Impact factor: 3.923

3.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

4.  Lack of tumor necrosis factor alpha induces impaired proliferation of hepatitis B virus-specific cytotoxic T lymphocytes.

Authors:  Senji Kasahara; Kazuki Ando; Kuniaki Saito; Kenji Sekikawa; Hiroyasu Ito; Tetsuya Ishikawa; Hiroo Ohnishi; Mitsuru Seishima; Shinichi Kakumu; Hisataka Moriwaki
Journal:  J Virol       Date:  2003-02       Impact factor: 5.103

5.  Gene transfer of costimulatory molecules into a human colorectal cancer cell line: requirement of CD54, CD80 and class II MHC expression for enhanced immunogenicity.

Authors:  M Lindauer; W Rudy; B Gückel; M V Doeberitz; S C Meuer; U Moebius
Journal:  Immunology       Date:  1998-03       Impact factor: 7.397

6.  Clinical Significance of BTLA, CD27, CD70, CD28 and CD80 as Diagnostic and Prognostic Markers in Ovarian Cancer.

Authors:  Janina Świderska; Mateusz Kozłowski; Maria Gaur; Ewa Pius-Sadowska; Sebastian Kwiatkowski; Bogusław Machaliński; Aneta Cymbaluk-Płoska
Journal:  Diagnostics (Basel)       Date:  2022-01-20
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.